Breast cancer - HealthQuill

Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered at a “fair price.”

UK watchdog blocks AstraZeneca, Daiichi’s breast cancer drug

Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered.

by HealthQuill
July 29, 2024
0 Comments

AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.

Drugs Health Pharma

AstraZeneca’s trial breast cancer drug fails to meet primary goals

AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.

by HealthQuill
June 18, 2024
0 Comments

AstraZeneca, Daiichi’s breast cancer drug trial results show improvement in progression-free survival

Drugs Health Pharma

AstraZeneca, Daiichi’s breast cancer drug trials show rise in survival

HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.

by HealthQuill
June 3, 2024
0 Comments

Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion.

Drugs Health Pharma

Novartis AG to buy Mariana Oncology for $1 billion to build RLT assets

HQ Team May 2, 2024: Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion..

by HealthQuill
May 2, 2024
0 Comments

Australian scientists may have found a drug to treat triple-negative breast cancer without any toxic effects, according to a statement from the University of Adelaide.

Drugs Health Pharma

A new oral drug may stop triple-negative breast cancer in its tracks

HQ Team February 8, 2024: Australian scientists may have found a drug to treat triple-negative breast cancer without any toxic effects, according to.

by HealthQuill
February 8, 2024
0 Comments

More than 35 million people may have cancer in 2050 — an increase of 77% from 20 million new cases in 2022, according to a WHO report.

Drugs Health Pharma

Cancer cases set to rise by 77% to 35 million in 2050: WHO global survey

More than 35 million people may have cancer in 2050 — an increase of 77% from 20 million new cases in 2022, according.

by HealthQuill
January 31, 2024
0 Comments

Johnson & Johnson will buy Ambrx Biopharma, Inc., a company developing targeted chemotherapy treatments, for $2 billion in cash.

Drugs Health Pharma

J&J to purchase Ambrx Biopharma for $2 billion in all-cash deal

HQ Team January 8, 2023: Johnson & Johnson will buy Ambrx Biopharma, Inc., a company developing targeted chemotherapy treatments, for $2 billion in cash..